Existing IMCD Excipients Offering to be augmented with strong API Presence of newly acquired Entity

Specialty chemicals and food ingredients distributor IMCD N.V. (Rotterdam, The Netherlands)  announced that it has signed an agreement to acquire 100% of the outstanding shares of DCS Pharma AG (Basel, BS – Switzerland) in a two-step process for an undisclosed sum. 90% of the shares will be acquired at the closing of the transaction, the remaining 10% ca. two years later, effective 31. December 2021.

DCS Pharma, a distributor of Active Pharmaceutical Ingredients (“APIs”), traces its roots back to two Swiss distributors of products  for the pharma and the nutraceutical industry, the Pharma business of Dolder AG and ChemSwiss AG, which were merged in 2016. Today the company operates with a total of 64 employees in seven countries besides Switzerland, including Spain, Italy, Germany, Mexico and China. In 2018, it generated sales of CHF 68 mn, IMCD said in a statement.

IMCD further said it expects formulation and marketing synergies between the newly acquired API activities and its existing business, which is mainly focused on Excipients. Customers of DCS Pharma should benefit from a significantly increased network, according to its CEO Beat Berger.

No financial details were disclosed on the transaction, which is subject to fulfilling customary closing conditions.

Source: IMCD press release

HGE – DCG / 01.11.2019